A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors
Latest Information Update: 30 Jan 2026
At a glance
- Drugs ADCE B05 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ADCendo
Most Recent Events
- 30 Jan 2026 New trial record